VKT Pharma
VKT Pharma is an India-based pharmaceutical contract manufacturer of tablets, capsules, and pellets (solid oral dosage forms), serving global generic and brand pharmaceutical companies through CRAMS partnerships across 10+ countries with US FDA, EU GMP, and WHO GMP accreditations.
- Company typePrivate
- Founded2009
- HeadquartersHyderabad, India
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What VKT Pharma does
VKT Pharma Private Limited is an India-based pharmaceutical contract manufacturer and CRAMS (Contract Research and Manufacturing Services) provider founded in 2009 and headquartered in Hyderabad, Telangana. The company specializes in solid oral dosage forms—tablets, capsules, and ready-to-fill immediate or modified-release pellets—serving major generic and brand pharmaceutical companies across 10+ countries. Manufacturing is concentrated at a 16,320 sq.mt. facility in Srikakulam District, Andhra Pradesh, with five dedicated blocks covering OSD production (4.4 billion tablet/capsule nameplate capacity across three phases, of which 1.5 billion is currently operational), pellet manufacturing (360 MT/annum across two modules), central warehousing, administration, and engineering/utilities. VKT Pharma maintains cGMP accreditations from the Indian FDA (2015), WHO GMP (2016 and 2017), the US FDA (June 2018), and the EU GMP (July 2018), enabling supply into regulated generics markets globally. The 25,000 sq.ft in-house R&D center covers formulation development, analytical development, and a pilot plant.
The product portfolio spans commercial pellets (Omeprazole 8.5%/9.0%, Itraconazole 20%/22%/32.25%, Esomeprazole 8.5%, Duloxetine 17%), finished formulations (Ranitidine 150/300 mg, Levetiracetam 250–1000 mg, Tadalafil 2.5–20 mg), and an active development pipeline that includes anti-retroviral tablets and capsules (Darunavir, Tenofovir/Emtricitabine, Atazanavir/Ritonavir, Lopinavir/Ritonavir), higher-strength and MUPS-based pellets, gastro-retentive systems, and bi-layered tablets. Technological capabilities include Para IV first-to-file products with 180-day exclusivity, modified-release formulations (delayed, extended, sustained release), colon-specific pellet targeting, bioequivalence/IVIVC development, and taste-masking. Revenue is generated through three streams: CRAMS (end-to-end formulation to commercial manufacturing), product-specific development and manufacturing partnerships with deal structures ranging from free-for-service to profit-sharing, and the sale of finished solid dosage form products. Pricing is not publicly disclosed and is negotiated on a project-by-project basis.
VKT Pharma operates as an associate company of SMS Pharmaceuticals Ltd, with P. Ramesh Babu serving as Chairman & Managing Director of both entities and P. Vamsi Krishna as Director. The company employs 251–500 people and follows a B2B sales-led go-to-market, reaching customers through strategic partnerships, joint ventures, and alliances with "highly reputed Pharma majors." In November 2025, VKT Pharma received US FDA approval for its reformulated Ranitidine tablets, marking the drug's return to the US market after a five-year absence due to NDMA impurity concerns—an event that drove an 18% share price increase in parent SMS Pharmaceuticals. The company has not disclosed any private equity or venture capital ownership.
VKT Pharma firmographics
Firmographics- Name
- VKT Pharma
- Legal name
- VKT Pharma Private Limited
- Website
- https://vktpharma.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- VKT Pharma is an India-based pharmaceutical contract manufacturer of tablets, capsules, and pellets (solid oral dosage forms), serving global generic and brand pharmaceutical companies through CRAMS partnerships across 10+ countries with US FDA, EU GMP, and WHO GMP accreditations.
- Ownership category
- akta.pro rank
VKT Pharma industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industry
- GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where VKT Pharma is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices2 records
Markets served
VKT Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure, Marketing or Sales
Revenue model
- Contract Research and Manufacturing Services (CRAMS): VKT Pharma offers Contract Research and Manufacturing Services (CRAMS) providing pharmaceutical companies with end-to-end solutions from product development to delivery. Services include formulation development, analytical development, regulatory affairs, and commercial manufacturing.
- Generic Product Development and Manufacturing Partnerships: Customized deal structures ranging from Free-For-Service to Profit Sharing collaborations for Generic Product development and manufacturing partnerships. Focus on Therapeutically Equivalent ANDA-based products, OTC and other products on a case-by-case basis.
- Finished Solid Dosage Form Products: Manufacturing and sale of finished solid dosage forms including Tablets (Ranitidine, Levetiracetam, Tadalafil), Capsules, and Pellets (Omeprazole, Itraconazole, Esomeprazole, Duloxetine) across various therapeutic segments.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
VKT Pharma product offering
Product offeringCore offering
VKT Pharma is a vertically integrated pharmaceutical company that manufactures and supplies tablets, capsules, and ready-to-fill immediate or modified-release pellets for generic drug formulations. The company offers Contract Research and Manufacturing Services (CRAMS), Novel Drug Delivery Systems (NDDS), and end-to-end pharmaceutical solutions spanning product development, formulation development, analytical development, regulatory affairs, and commercial manufacturing across a wide range of therapeutic segments including anti-ulcer, anti-fungal, anti-depressant, anti-retroviral, anti-epileptic, and BPH treatments.
Product overview
VKT Pharma is a quality-driven pharmaceutical company with vertically integrated operations spanning the entire pharmaceutical value chain from product development to delivery. The company specializes in Research & Development, Manufacturing and Marketing of Solid Dosage Forms with focus on Tablets, Capsules & Ready to Fill Immediate or Modified release Pellets. The core product portfolio includes Commercial Pellets (Omeprazole, Itraconazole, Esomeprazole, Duloxetine), Finished Formulations (Ranitidine Tablets, Levetiracetam Tablets, Tadalafil Tablets), and an extensive development pipeline including anti-retroviral products. The company offers Contract Research and Manufacturing Services (CRAMS) and Novel Drug Delivery Systems (NDDS) alongside formulation development services. Manufacturing operations are conducted across dedicated blocks: Block A (OSD - 4.4Bn tablets/capsules capacity), Block B (Pellets - 360 MT/annum capacity), and Block C (Central Warehouse).
Differentiator
Problem solved
Functional benefit
Products and services
- Commercial Pellets (Omeprazole, Itraconazole, Esomeprazole, Duloxetine) Commercially available pharmaceutical pellets including Omeprazole Pellets (8.5% & 9.0%), Itraconazole Pellets (20%, 22% & 32.25%), Esomeprazole Pellets (8.5%), and Duloxetine Pellets (17%) for anti-ulcer, anti-fungal, and anti-depressant therapeutic segments.
- Ranitidine Tablets (150mg, 300mg) Ranitidine Tablets in 150mg and 300mg strengths for anti-ulcer treatment, recently approved by US FDA after reformulation addressing NDMA impurity concerns.
- Levetiracetam Tablets (250mg, 500mg, 750mg, 1000mg) Levetiracetam Tablets in 250mg, 500mg, 750mg, and 1000mg strengths for anti-epileptic treatment.
- Tadalafil Tablets (2.5mg, 5mg, 10mg, 20mg) Tadalafil Tablets in 2.5mg, 5mg, 10mg, and 20mg strengths for erectile dysfunction (ED) treatment.
- Formulation Development Services Comprehensive formulation development for tablets (immediate release, delayed release, extended release, sustained release, bi-layered, coated, MUPs, fixed dose combinations, gastro-retentive systems, sublingual), capsules, pellets, liquid orals, and powders/granules.
- Contract Research and Manufacturing Services (CRAMS) End-to-end pharmaceutical solutions from research to delivery of finished products, including 505(b)(2) and new drug product development, platform technology analysis, and regulatory support.
Quantifiable outcome
- First-to-file status and 180 days exclusivity achieved for number of Para IV products
- +1 more outcomes
Companies that use VKT Pharma
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
VKT Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
VKT Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- SMS Pharmaceuticals LtdcoreSMS Pharmaceuticals Ltd is the parent/associate company of VKT Pharma. VKT Pharma operates as an associate firm under the SMS Group. The relationship provides strategic alignment and shared resources within the Indian pharmaceutical industry. SMS Pharma's stock performance (18% gain following VKT's US FDA approval) demonstrates the strategic importance of this partnership.
Scale indicators6 records
Recent moves8 records
Expansion highlights5 records
VKT Pharma competitors and assessment
Company assessmentBroad incumbents
- Hetero Labs: Indian pharmaceutical company with strong ARV franchise and formulation manufacturing capabilities; comparable through its presence in VKT's anti-retroviral development pipeline space and its generic solid-dosage manufacturing for global markets.
- Divis Laboratories: Indian API and intermediates manufacturer with growing formulation services and strong regulatory credentials; competes in the CDMO and complex generics space that VKT targets, particularly for global pharma partners.
- Aurobindo Pharma: Large Indian pharmaceutical company with substantial generic finished dosage, API, and ARV franchises plus US FDA-approved facilities; competes for similar CRAMS and generic formulation contracts although at a much larger scale.
- Dr. Reddy's Laboratories: Major Indian generics and CDMO player with US FDA-inspected facilities offering formulation development, contract manufacturing, and complex generics including modified-release products, overlapping VKT's target market.
- Piramal Pharma Solutions: Global CDMO with development and manufacturing capabilities across sterile injectables, oral solids, and APIs; directly comparable in CRAMS service offering but operates at much larger scale across multiple geographies.
Emerging players
- Laurus Labs: Indian CDMO with API, formulation, and CRO services targeting global pharma; comparable to VKT as a mid-sized Indian player pursuing regulated-market manufacturing and complex formulation services.
Direct peers
- Granules India: Indian pharmaceutical manufacturer focused on finished dosages, API, and intermediates with strong pellet and tablet capabilities serving global generic markets; highly comparable to VKT in product mix (tablets, capsules, pellets) and CRAMS-style services targeting regulated markets.
- Natco Pharma: Indian pharmaceutical company specializing in complex generics and Para IV filings for the US market, with strong modified-release and oncology product development; closely comparable to VKT's complex-generics, Para IV, and first-to-file focus.
- SMS Pharmaceuticals: Parent/associate company of VKT Pharma and a leading Indian API manufacturer with growing formulation interests; shares leadership, strategic alignment, and Hyderabad base, making it the most direct comparability benchmark for VKT's operations.
- ScieGen Pharmaceuticals: US-based but India-manufactured generic pharmaceuticals producer focused on solid oral dosage forms with US FDA-approved facilities; similarly positioned as a mid-tier CDMO/generic player competing for outsourced manufacturing partnerships and complex generic approvals.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
VKT Pharma social profiles
Digital presenceVKT Pharma compliance and trust
Trust signalCompliance4 records
VKT Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
VKT Pharma leadership team
Management profileNumber of profiles
Profiles2 records
VKT Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VKT Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VKT Pharma
What does VKT Pharma do?
VKT Pharma is a vertically integrated pharmaceutical company that manufactures and supplies tablets, capsules, and ready-to-fill immediate or modified-release pellets for generic drug formulations. The company offers Contract Research and Manufacturing Services (CRAMS), Novel Drug Delivery Systems (NDDS), and end-to-end pharmaceutical solutions spanning product development, formulation development, analytical development, regulatory affairs, and commercial manufacturing across a wide range of therapeutic segments including anti-ulcer, anti-fungal, anti-depressant, anti-retroviral, anti-epileptic, and BPH treatments.
Is VKT Pharma a public or private company?
VKT Pharma is a private company. It is classified as corporate owned and is currently operating.
When was VKT Pharma founded?
VKT Pharma was founded in 2009. It employs 251 to 500 people.
Where is VKT Pharma based?
VKT Pharma is headquartered in Hyderabad, India, in the Asia region.
How does VKT Pharma make money?
Three revenue lines are on record. Contract Research and Manufacturing Services (CRAMS) is the primary driver. The others are generic Product Development and Manufacturing Partnerships and finished Solid Dosage Form Products.
Who are VKT Pharma's main competitors?
Broad incumbents on record are Hetero Labs, Divis Laboratories, Aurobindo Pharma, Dr. Reddy's Laboratories and Piramal Pharma Solutions. Laurus Labs is listed as an emerging player. Direct peers are Granules India, Natco Pharma, SMS Pharmaceuticals and ScieGen Pharmaceuticals.
Does VKT Pharma have an API?
No public API is recorded for VKT Pharma.
What industry is VKT Pharma in?
VKT Pharma's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 325412 and its SIC code is 2834.